Actively Recruiting
Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Led by ImmunityBio, Inc. · Updated on 2026-05-04
10
Participants Needed
3
Research Sites
183 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Open Label, Phase 1 study of CD19 t-haNK as a single agent and combination with rituximab in subjects with selected CD19+ and CD20+ R/R B-cell non-Hodgkin Lymphoma( NHL).
CONDITIONS
Official Title
Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Able to understand and provide signed informed consent
- Histologically confirmed CD19- and CD20-positive B-cell non-Hodgkin lymphoma, excluding primary CNS lymphoma, CLL, and Burkitt lymphoma
- Completed at least 2 lines of cytotoxic chemotherapy
- Prior treatment with rituximab or another anti-CD20 antibody
- Measurable disease by Lugano classification within 8 weeks before consent
- CD19 and CD20 positivity of at least 5% confirmed by biopsy or flow cytometry
- ECOG performance status of 0 to 1
- Expected survival of more than 16 weeks
- Willingness to comply with study procedures
- Ability to attend all required study visits and follow-up
- Agreement to use effective contraception during the study and for 5 months after last dose (for females of childbearing potential and nonsterile males)
You will not qualify if you...
- Diagnosis of primary CNS lymphoma, chronic lymphocytic leukemia (CLL), Burkitt or Burkitt-like lymphoma
- Known allergy to sulfa-containing medications or history of anaphylaxis to sulfa
- Allergy to human albumin or dimethyl sulfoxide (DMSO)
- Serious uncontrolled diseases that increase risk of treatment complications
- Significant autoimmune disease or active uncontrolled autoimmune conditions requiring high-dose steroids
- History of allogeneic hematopoietic stem-cell transplant needing ongoing graft-versus-host disease therapy
- Anti-CD20 antibody treatment within 2 weeks before cell infusion
- History of organ transplant requiring immunosuppression
- Development of high-grade lymphomas or leukemias after solid organ transplant
- CD19- and CD20-positive metastases to the central nervous system
- Nonmalignant central nervous system diseases such as stroke or epilepsy
- History or active inflammatory bowel disease
- Inadequate organ function based on specific blood count and liver/kidney test thresholds
- Uncontrolled hypertension or serious cardiovascular conditions within 6 months prior to treatment
- Chronic daily systemic corticosteroid use over 3 months at doses above 20 mg prednisone equivalent
- Use of medications with known adverse interactions with study drugs
- Positive tuberculosis test
- HIV infection with low CD4 count and detectable viral load
- Active hepatitis B infection
- Concurrent active cancers other than certain skin cancers
- Inability or unwillingness to follow study protocol
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
FARMOVS
Bloemfontein, Free State, South Africa, 9301
Actively Recruiting
2
Dr. Jackie Thomson Inc.
Johannesburg, Gauteng, South Africa, 2193
Actively Recruiting
3
Albert Cellular Therapy
Pretoria, Gauteng, South Africa, 0044
Actively Recruiting
Research Team
K
Kayleigh Russell
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here